Fig. 3

COPS3 enhances the migratory and invasive abilities of osteosarcoma cells. a and b 143B and HOS cells stably transfected with shCOPS3 or shCtrl were treated with or without MAPK/ERK inhibitor U0126 (1 μM) for 24 h, migratory and invasive abilities were evaluated by transwell assay (a). Wound-healing assay was also performed to analyze the migratory ability (b). c and d SAOS-2 cells transfected with Ad-COPS3 were exposed to MAPK/ERK inhibitor U0126 (1 μM) for 24 h, migration and invasion of the cells were analyzed by transwell (c) and Wound-healing assay (d). Scale bars: 100 μm. Each experiment was repeated three times, the data represented the mean ± S.D. **P < 0.01 vs. shCtrl group (a and b) or the Ad-NC group (c and d)